Background: An analysis of medical records of young females who were examined in our department during a five-year period females not taking HC, PE was detected in only 3 patients (10%).
Introduction
Pulmonary embolism (PE) is a common, serious, but treatable medical condition caused by migration of a thrombus to the pulmonary circulation, usually from the veins of the lower extremities [1] . It can cause death or lead to chronic thromboembolic pulmonary hypertension at any age. In recent years, the number of young females treated for PE or deep-vein thrombosis in the legs has been increasing in the Czech Republic. Hormonal contraception (HC) is an effective form of contraception used by 100 million women world-wide. While its effect on the incidence of 
Material and methods
The patients group consisted of 86 females aged 15-25 years.
(mean age 21 years) who had undergone a V/P scan. Seventeen of them were examined repeatedly with 1-2 control perfusion after PE. Altogether, 114 scintigraphic examinations were performed.
V/P scan with planar imaging was done using a planar gamma camera (Mediso MB 9200) in 4 projections. Perfusion studies were performed with the use of 
Evaluation
In our study we evaluated our findings according the recommended criteria PIOPED II [1, 3] .
Results
The incidence of PE in relation to hormonal contraception use in our group of patients is presented in Table 1. 1. 57/86 (66%) of our patients were using HC.
2. Among the 57 on HC, 24 (42%) had scintigraphic signs of PE. 
Discussion
PE presents with recognized patterns of symptoms that may include unexplained breathlessness, chest pain (central or pleuritic), cough, haemoptysis, syncope, palpitations, tachypnoea, tachycardia (heart rate > 100 bpm), cyanosis, fever, hypotension (systolic blood pressure < 100 mm Hg), right heart failure, pulmonary hypertension, and leg swelling. V/P scan is more readily available than MDCT but access to both techniques is vital for the diagnosis of PE. MDCT is often contraindicated for complications including an allergy or contrast-agent extravasation. By contrast, a V/P scan has no contraindications, complications do not occur, and it carries a much lower radiation burden than MDCT. Therefore, V/Pscan is recommended as a first-line procedure in young patients, especially females, with suspected PE [3, 4] .
The main indication for V/P scan in our study were successive PEs, commonly caused by migration of a thrombus to the pulmonary circulation. Usually, this is due to the embolism of a blood clot from the deep veins in the legs, a process termed venous thromboembolism (VTE).
Multiple risk factors of VTE are congenital and acquired [5] .
Congenital genetic causes of the hypercoagulable state: antithrombin III deficiency, deficiency of the other coagulative inhibitors, C and S protein deficiency, factor II deficiency (prothrombin deficiency), and factor V Leiden mutation. Acquired predisposition of VTE: extensive varicose vein, obesity, trauma, surgery, malignancy, antiphospholipid syndrome, and some kinds of medication -not least HCs. A more recently recognized risk factor is long-distance flights, even in healthy individuals [6] . It is well known that the use of oestrogen-progesterone-OC gives rise to a risk of VTE. Therefore, lower oestrogen medication has begun to be applied in common practice, but a risk of VTE persists. VTE risk depends, in addition to the oestrogens, on the presence of progestin and its types as well. In the literature more papers were noted which were devoted to the effect of OC use on the emer- gence of VTE risk [7, 8] ; a few of them compared and assessed the VTE risk in third-and second-generation OCs [9, 10] . For VTE development, time is also very important -how long a woman uses OCs [11] . The risk of venous thrombosis in current users of hormone-releasing intrauterine devices were not associated with any increased risk of venous thrombosis [12] .
The relatively small risk of VTE attributable to oral HC use may interact geometrically with the procoagulant mutations and the combination of the mutations in the prothrombin gene, and factor V Leiden is associated with a greater risk of thrombosis.
The relative risk for VTE in women who have this station is approximately 35 for OC users compared with nonusers [13] .
Leiden mutation was the most frequent finding in our group of patients. Two thirds of our patients used per oral HCs. But that is a big heterogeneous group in which women were medicated with different sorts of HCs (second or third generation oral contraceptives) and during different time periods (1-7 years).
Overall, the young women who have undergone PE are not numerous, but the prevention of this life-threatening status should be more consistent with a detailed personal and family history of VTE and timely examination of their thrombotic profile before OC pill prescription.
Conclusions
The majority of our patients who underwent a V/P used HC.
PE was confirmed by scintigraphy in 42% of them. In comparison, only 10% of females not using HC were positive for PE. 42% of patients with PE had persistent postembolic changes.
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Original
The risk of venous thromboembolism related to the use of HC is well known. Our study indicates that VTE needs to be considered as a cause of PE even in very young females.
In our experience, prevention of this life-threatening status in patients with family history of venous thromboembolism consists of timely examination of their thrombotic profile and selection of appropriate contraception.
